Hep C Quickly Fades with an Oral Investigational Drug Combo
Share
Follow Us
AASLD: Oral HCV Combo Yields Rapid Response
By Michael Smith, North American Correspondent, MedPage Today
Published: November 11, 2011
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
SAN FRANCISCO — A combination of two investigational antiviral drugs with different mechanisms of action against hepatitis C virus (HCV) yielded quick and persistent responses in previous nonresponders without the use of pegylated interferon, a researcher said here.
By week eight of treatment — and at every measurement thereafter — HCV was undetectable in all nine patients who completed treatment in the phase 2b study, according to Kazuaki Chayama, MD, PhD, of Hiroshima University in Hiroshima, Japan.
Continue reading this entire article:
http://www.medpagetoday.com/MeetingCoverage/AASLD/29610
